A Phase IIb clinical trial for IFX-1 in hidradenitis suppurativa (HS) patients
Phase of Trial: Phase II
Latest Information Update: 28 Jun 2018
At a glance
- Drugs IFX 1 (Primary)
- Indications Hidradenitis suppurativa
- Focus Adverse reactions
- 28 Jun 2018 According to InflaRx media release, study will be conducted in approximately 20 sites in the U.S.
- 28 Jun 2018 According to InflaRx media release, company announced the approval of their Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA). The open IND will allow InflaRx to start this study.
- 15 May 2018 New trial record